U.S. Markets closed
  • S&P 500

    +8.70 (+0.24%)
  • Dow 30

    +37.90 (+0.13%)
  • Nasdaq

    +111.44 (+0.92%)
  • Russell 2000

    +10.25 (+0.56%)
  • Crude Oil

    -0.18 (-0.39%)
  • Gold

    -23.10 (-1.28%)
  • Silver

    -0.81 (-3.46%)

    +0.0057 (+0.4788%)
  • 10-Yr Bond

    -0.0360 (-4.10%)
  • Vix

    -0.41 (-1.93%)

    -0.0042 (-0.3169%)

    -0.2000 (-0.1918%)

    -36.37 (-0.21%)
  • CMC Crypto 200

    -4.23 (-1.25%)
  • FTSE 100

    +4.65 (+0.07%)
  • Nikkei 225

    +107.40 (+0.40%)

Emerging Markets Report: $2.5 Billion Reasons

ORLANDO, FL / ACCESSWIRE / February 21, 2019 / Earlier this week, cannabis testing lab Digipath Inc. (DIGP) found out that the Company had been identified as one of the "The top 10 industry players operating in the market of cannabis testing across the globe" alongside some of the largest and most popular brands in the industry. In a highly competitive emerging market, this is strong news for the Nevada-based operator with an evolving business model that includes expansion into Colombia and California for cannabis and hemp testing and North Carolina, Oregon and Arizona for hemp testing.

But what might have been most beneficial to Digipath isn't the prestigious inclusion among industry stalwarts. What might be most important is that independent research firm Insight Partners believes that the international cannabis testing market will expand from $1 Billion in 2017 to $2.5 Billion in 2025, with a compound annual growth rate of 11.9% from 2017-2025.

Factor in that more and more countries are legalizing cannabis, which in nearly every instance requires testing, and the market expansion is understandable. It is worth noting that the report, which has an end date assumption of 2025, may not fully consider other countries or states that could decide to legalize closer to 2025 and aren't a part of that projection. Of course, the report likely does not factor in any possible contraction or adverse regulation to growth either but at present we're seeing little of the sort.

It also warrants consideration that broad use of CBD could create a Malcolm Gladwell-esque tipping point, and that there could be an accelerated market appetite for CBD and hemp.

Perhaps it's the nexus of the report's inclusion of Digipath in the list of top 10 industry players in the cannabis testing industry and the bold prediction of market growth that are compelling because if Digipath can ratify that Top 10 designation with relative market share the Company will certainly be worth watching.

For an Investor's Introduction to Digipath please visit Digipath Investor Info.

About Digipath, Inc. & Digipath Labs, Inc.

Digipath, Inc. supports the cannabis industry's best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry.

Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization.

About Emerging Markets Report

Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor-relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.

For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php

Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.

We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.

EMC has been paid 40000 by Digipath for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. A contributor to this report holds 400,000 shares and receives $3,500 a month for a period of six months for investor relations services on the behalf of Digipath.


Emerging Markets Consulting, LLC
E-mail: jamespainter@emergingmarketsllc.com
Web: www.emergingmarketsllc.com

SOURCE: Emerging Markets Report

View source version on accesswire.com: